Table 1.

Clinicopathologic features

Age, median (range)	69 yr (37–82)
Gender
M	56% (n = 9)
F	44% (n = 7)
Ethnicity
Caucasian, non-Hispanic	75% (n = 12)
Caucasian, Hispanic	6% (n = 1)
African American	19% (n = 3)
Smoking history
Never	38% (n = 6)
Former	62% (n = 10)
Pack year history, median (range)	4 pack years (0–45)
Number of prior systemic therapies, median (range)	2 (1–4)
Histology
Adenocarcinoma	100% (n = 16)
Invasive mucinous adenocarcinoma	44% (n = 7)

The demographics, stage, smoking history, number of prior systemic therapies, and histology of 16 patients with KRAS G12D-mutant lung adenocarcinomas treated with bortezomib on this phase 2 trial are summarized.